The Role of a Cachexia Grading System in Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: Implications for Survival

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Barrón-Barrón F, Guzmán-De Alba E, Alatorre-Alexander J, Aldaco-Sarvider F, Bautista-Aragón Y, Blake-Cerda M, Blanco-Vázquez YC, Campos-Gómez S, Corona-Cruz JF, Iñiguez-García MA, et al. National clinical practice guidelines for the management of non-small cell lung cancer in early, locally advanced and metastatic stages. Extended version. Salud Publica Mex. 2019;61(3):359–414. doi:10.21149/9916
   PubMed Web of Science ®Google Scholar
• Rolfo C, Caglevic C, Santarpia M, Araujo A, Giovannetti E, Gallardo CD, Pauwels P, Mahave M. Immunotherapy in NSCLC: A promising and revolutionary weapon. Adv Exp Med Biol. 2017;995:97–125. doi:10.1007/978-3-319-53156-4_5
   PubMed Web of Science ®Google Scholar
• Barron F, Zatarain-Barron ZL, Cardona AF, Arrieta O. Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century. J Thorac Dis. 2018;10(3):1265–8. doi:10.21037/jtd.2018.03.28
   PubMed Web of Science ®Google Scholar
• Dempke WCM, Fenchel K, Dale SP. Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree? Transl Lung Cancer Res. 2018;7(Suppl 3):S275–S279. doi:10.21037/tlcr.2018.04.18
   PubMed Web of Science ®Google Scholar
• Magri V, Gottfried T, Di Segni M, Urban D, Peled M, Daher S, Stoff R, Bar J, Onn A. Correlation of body composition by computerized tomography and metabolic parameters with survival of nivolumab-treated lung cancer patients. Cancer Manag Res. 2019;11:8201–7. doi:10.2147/CMAR.S210958
   PubMed Web of Science ®Google Scholar
• Labomascus S, Fughhi I, Bonomi P, Mcdonald A, Batus M, Fidler MJ, Basu S, Borgia J. P2.01-61 Body mass index over time is associated with overall survival in advanced NSCLC patients treated with immunotherapy. J Thoracic Oncol. 2018;13(10):S688. doi:10.1016/j.jtho.2018.08.1115
   Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. doi:10.1016/S1470-2045(10)70218-7
   PubMed Web of Science ®Google Scholar
• Martin L, Senesse P, Gioulbasanis I, Antoun S, Bozzetti F, Deans C, Strasser F, Thoresen L, Jagoe RT, Chasen M, et al. Diagnostic criteria for the classification of cancer-associated weight loss. JCO. 2015;33(1):90–9. doi:10.1200/JCO.2014.56.1894
   PubMed Web of Science ®Google Scholar
• Laviano A, Koverech A, Mari A. Cachexia: clinical features when inflammation drives malnutrition. Proc Nutr Soc. 2015;74(4):1–7. doi:10.1017/S0029665115000117
   PubMed Web of Science ®Google Scholar
• Arrieta O, De la Torre-Vallejo M, López-Macías D, Orta D, Turcott J, Macedo-Pérez E-O, Sánchez-Lara K, Ramírez-Tirado L-A, Baracos VE. Nutritional status, body surface, and low lean body mass/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non-small cell lung cancer. Oncologist. 2015;20(8):967–74. doi:10.1634/theoncologist.2015-0058
   PubMed Web of Science ®Google Scholar
• Sánchez-Lara K, Turcott JG, Juárez E, Guevara P, Núñez-Valencia C, Oñate-Ocaña LF, Flores D, Arrieta O. Association of nutrition parameters including bioelectrical impedance and systemic inflammatory response with quality of life and prognosis in patients with advanced non-small-cell lung cancer: a prospective study. Nutr Cancer. 2012;64(4):526–34. doi:10.1080/01635581.2012.668744
   PubMed Web of Science ®Google Scholar
• Turcott JG, Del Rocío Guillen Núñez M, Flores-Estrada D, Oñate-Ocaña LF, Zatarain-Barrón ZL, Barrón F, Arrieta O. The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial. Support Care Cancer. 2018;26(9):3029–38. doi:10.1007/s00520-018-4154-9
   PubMed Web of Science ®Google Scholar
• Kiss N, Isenring E, Gough K, Wheeler G, Wirth A, Campbell BA, Krishnasamy M. Early and intensive dietary counseling in lung cancer patients receiving (chemo)radiotherapy-a pilot randomized controlled trial. Nutr Cancer. 2016;68(6):958–67. doi:10.1080/01635581.2016.1188972
   PubMed Web of Science ®Google Scholar
• Turcott JG, Juarez-Hernandez E, Sanchez-Lara K, Flores-Estrada D, Zatarain-Barron ZL, et al. Baseline dysgeusia in chemotherapy-naive non-small cell lung cancer patients: association with nutrition and quality of life. Nutr Cancer. 2019;72(2):1–8. doi:10.1080/01635581.2019.1633362
   PubMed Web of Science ®Google Scholar
• Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hütterer E, Isenring E, Kaasa S, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48. doi:10.1016/j.clnu.2016.07.015
   PubMed Web of Science ®Google Scholar
• Turner DC, Kondic AG, Anderson KM, Robinson AG, Garon EB, Riess JW, Jain L, Mayawala K, Kang J, Ebbinghaus SW, et al. Pembrolizumab exposure-response assessments challenged by association of cancer cachexia and catabolic clearance. Clin Cancer Res. 2018;24(23):5841–9. doi:10.1158/1078-0432.CCR-18-0415
   PubMed Web of Science ®Google Scholar